Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
SEP-479 oral small-molecule agonist of the parathyroid hormone 1 receptor (PTH1R) aimed at treating hypoparathyroidism Recent Highlights: In May 2025, Septerna signed an exclusive global collaboration with Novo Nordisk worth up to $2.2B to co-develop oral small molecule GLP-1, GIP, and glucagon receptor agonists
Backed by Quests scientific innovation, it offers a reliable, effective way to harness curcumins full therapeutic potential
In the CY 2008 OPPS/ASC final rule with comment period (72 FR 66857 through 66858), we set out a step-by-step illustration of the final budget neutrality adjustment calculation based on the methodology finalized in the August 2, 2007 ASC final rule (72 FR 42521 through 42531) and as applied to updated data available for the CY 2008 OPPS/ASC final rule with comment period
It manufactures Pharmaceutical finished formulations, Dietary Supplements & Cosmeceutical Products
10.1083/jcb.200407094 J
